Reducing Life-threatening and Disabling Hemorrhagic Conditions

Our patented technology aims to address unmet medical needs by using an innovative mechanism of action to inhibit fibrinolysis.

MECHANISM OF ACTION

A Novel Antifibrinolytic Strategy

read more

UNMET MEDICAL NEEDS

Life-threatening Hemorrhages

read more

THE EVIDENCE

89% Reduced Bleeding Time in Preclinical In-vivo Animal Models

read more
A Novel Antifibrinolytic Strategy

Hemostatics is developing CM-352, a novel antifibrinolytic agent to reduce bleeding in life-threatening and disabling hemorrhagic conditions.
With a new mechanism of action to inhibit fibrinolysis, our patented preclinical candidate is addressing significant unmet medical needs (e.g. IntraCranial Hemorrhage where other treatments are still suboptimal).

A Novel Antifibrinolytic Strategy

Hemostatics is developing CM-352, a novel antifibrinolytic agent to reduce bleeding in life-threatening and disabling hemorrhagic conditions.
With a new mechanism of action to inhibit fibrinolysis, our patented preclinical candidate is addressing significant unmet medical needs (e.g. IntraCranial Hemorrhage where other treatments are still suboptimal).

Targeted Conditions

Surgery

Major Surgeries

Significant blood loss occurs in 3% of the 100-120 millions of major surgeries every year in the 7 major markets. Cardiac surgery is the largest consumer of blood transfusion products.

read more

Trauma

Trauma

Hemorrhage is responsible of 45% of deaths occurring within 24h after traumatic injury.

read more

ICH

IntraCerebral Hemorrhage

IntraCerebral Hemorrhage (ICH) accounts for approx. 20% of all strokes, with a case fatality rate of 54% at 1 year. There is currently no treatment to stop hemorrhage or prevent hemorrhage enlargement.

read more

Gynecology

GYNECOLOGY

Several gynecological conditions are caused by an excess of bleeding (Heavy Menstrual Bleeding, Postpartum Bleeding, Cesaren, etc.).

read more

RARE DISEASES

RARE DISEASES

Several Bleeding Disorders are associated with hemorrhage (Hereditary Angioedema, Hemophilia, etc.).

read more

GI BLEEDING

GASTROINTESTINAL BLEEDING

Acute gastrointestinal (GI) bleeding is a potentially life-threatening emergency and common cause of hospitalization.

read more

We Partner With Leading Experts in the Fields of Science, Healthcare, and Business

Exceptional Accomplishments Power the Holistic Success of Hemostatics

3

PATENTS
Strong IP position: 2 patents on novel drug formulas and 1 patent protecting the mechanism against known inhibitors repositioning.

89%

BLEEDING TIME DECREASE
CM-352 reduces Bleeding Time in mice by 89%.

61%

BLOOD LOSS DECREASE
CM-352 reduces Blood Loss by 61% in a Tail Bleeding mice model.

4

PRECLINICAL MODELS
Efficacious in 4 different preclinical animal models of bleeding. Optimal profile for i.v. administration, ideal for short term control of bleeding.

Want To Start Investing With Us?
Investing in the novel biopharmaceutical technology of Hemostatics can help accelerating the development of innovative solutions addressing potentially life-threatening hemorrhagic conditions.